No DFS Benefit: Adjuvant Docetaxel in Higher-Risk Prostate Ca

In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT.

Source: CancerNetwork - June 10, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news